Sevikar 40 mg/10 mg filmovertrukne tabletter Dinamarca - danés - Lægemiddelstyrelsen (Danish Medicines Agency)

sevikar 40 mg/10 mg filmovertrukne tabletter

daiichi sankyo europe gmbh - amlodipinbesilat, olmesartan medoxomil - filmovertrukne tabletter - 40 mg/10 mg

Sevikar 40 mg/5 mg filmovertrukne tabletter Dinamarca - danés - Lægemiddelstyrelsen (Danish Medicines Agency)

sevikar 40 mg/5 mg filmovertrukne tabletter

daiichi sankyo europe gmbh - amlodipinbesilat, olmesartan medoxomil - filmovertrukne tabletter - 40 mg/5 mg

Cometriq Unión Europea - danés - EMA (European Medicines Agency)

cometriq

ipsen pharma - cabozantinib - thyroid neoplasms - antineoplastiske midler - behandling af voksne patienter med progressiv, inoperabel lokalt fremskreden eller metastatisk medullær thyroid carcinoma.

Lojuxta Unión Europea - danés - EMA (European Medicines Agency)

lojuxta

amryt pharmaceuticals dac - lomitapide - hyperkolesterolæmi - lipid modificerende midler - lojuxta er indiceret som et supplement til en low‑fat kost og andre lipid‑lowering lægemidler med eller uden lav density lipoprotein (ldl) aferese hos voksne patienter med homozygot familiær hyperkolesterolæmi (hofh). genetiske bekræftelse af hofh skal indhentes, når det er muligt. andre former for primær hyperlipoproteinaemia og sekundære årsager til hypercholesterolaemia e. nefrotisk syndrom, hypothyroidisme) skal udelukkes,.

Venclyxto Unión Europea - danés - EMA (European Medicines Agency)

venclyxto

abbvie deutschland gmbh co. kg - venetoclax - leukæmi, lymfocytisk, kronisk, b-celle - antineoplastiske midler - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly  diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.

Alea 20/5 mg filmovertrukne tabletter Dinamarca - danés - Lægemiddelstyrelsen (Danish Medicines Agency)

alea 20/5 mg filmovertrukne tabletter

menarini international operation - amlodipinbesilat, olmesartan medoxomil - filmovertrukne tabletter - 20/5 mg

Alea 40/10 mg filmovertrukne tabletter Dinamarca - danés - Lægemiddelstyrelsen (Danish Medicines Agency)

alea 40/10 mg filmovertrukne tabletter

menarini international operation - amlodipinbesilat, olmesartan medoxomil - filmovertrukne tabletter - 40/10 mg

Alea 40/5 mg filmovertrukne tabletter Dinamarca - danés - Lægemiddelstyrelsen (Danish Medicines Agency)

alea 40/5 mg filmovertrukne tabletter

menarini international operation - amlodipinbesilat, olmesartan medoxomil - filmovertrukne tabletter - 40/5 mg

Alea Comp 20+5+12,5 mg filmovertrukne tabletter Dinamarca - danés - Lægemiddelstyrelsen (Danish Medicines Agency)

alea comp 20+5+12,5 mg filmovertrukne tabletter

menarini international operation - amlodipinbesilat, hydrochlorthiazid, olmesartan medoxomil - filmovertrukne tabletter - 20+5+12,5 mg

Alea Comp 40+10+12,5 mg filmovertrukne tabletter Dinamarca - danés - Lægemiddelstyrelsen (Danish Medicines Agency)

alea comp 40+10+12,5 mg filmovertrukne tabletter

menarini international operation - amlodipinbesilat, hydrochlorthiazid, olmesartan medoxomil - filmovertrukne tabletter - 40+10+12,5 mg